From Nasdaq:



The stocks listed that reached a 52-week high within the week ending Dec.22, 2023 include: Syros Pharmaceuticals, Inc. (SYRS), ZimVie Inc. (ZIMV), Liquidia Corporation (LQDA), Karuna Therapeutics, Inc. (KRTX), Fusion Pharmaceuticals Inc. (FUSN), Calliditas Therapeutics AB (CALT), Apogee Therapeutics, Inc. (APGE), BrainsWay Ltd. (BWAY), ALX Oncology Holdings Inc. (ALXO), Autolus Therapeutics plc (AUTL), AC Immune SA (ACIU), KalVista Pharmaceuticals Inc. (KALV), Savara Inc. (SVRA), Arvinas Inc. (ARVN), Xenon Pharmaceuticals Inc. (XENE), Neurocrine Biosciences Inc. (NBIX), Insmed Inc. (INSM), CymaBay Therapeutics Inc. (CBAY), Innoviva Inc. (INVA), BridgeBio Pharma Inc. (BBIO), Medpace Holdings Inc. (MEDP), Alpine Immune Sciences Inc. (ALPN), Collegium Pharmaceutical Inc. (COLL), and Blueprint Medicines Corp. (BPMC).

The maximum gains since their respective publication prices range from 6% to 359% for these stocks that reached a 52-week high in the week ending Dec.22, 2023.

The last closing prices for these stocks range from $4.33 to $317.85, with percentage gains ranging from 6% to 359%.



Read more: These Biotech Stocks Climbed To New Peaks – Did You Invest?